The Dow Chemical Company

Igl Pharma Inc.

IP Liberty Vision Corporation

Dow Global Technolgoies LLC

Serene, LLC

Isotherapeutics Group LLC

Actinium Pharmaceuticals, Limited

Clear Vascular Inc.

Snip Holdings, Incorporated

Sorbent Therapeutics, Inc.

Jaime Simon

David A Wilson

R Keith Frank

Joseph R Garlich

Kenneth McMillan

Druce K Crump

Wynn A Volkert

William Jack Kruper, Jr

Deidre A Strand

Susan J Babinec

Garry E Kiefer

Alan D Strickland

David E Troutner

William F Goeckeler

Paul Theodore Finger

Toby Welles

Nigel Raymond Stevenson

William A Fordyce

Roberta C Cheng

Gilbert R Gonzales

Tipton T Masterson

Lance A Cooper

Walter L Vaughn

Vidyadhar Babu Hegde

Thomas H Kalantar

Mark T Bernius

Steven H Christiansen

Paul E Cranley

Harrell L Huff

Kelli R Jay

Josue Manuel Moreno Bermudez

Robert B Fletcher

Daniel J Macey

Kristine L Danowski

Teresa Littleton

Flor A Castillo

Richard Keith Frank

Robert J Michalowski

St George George

Douglas P White

Michelle A Pressler

Dana W Morin

Christopher M Jones

Davis A Wilson

William F Goeckleler

Sharon Braughman

Sharon Baughman

Dana W Simon

William F Goeckler

Zechariah David Sandlin

A Gaylord King

Bettina M Rosner

Keith R Frank

George St George

Peter Kip Mercure

Malcolm W Warren

Mark Sb Felix

Robert Paul Haley

Chris W Mcdougall

Larry Sun

This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two-part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression or bone marrow ablation.

DOTMP kit formulations for radioisotopes

A polymeric radiation-source with customized geometries to maximize receipt of radiation into treatment areas that is formed from either radioisotopes molecularly bonded to a polymer or radioisotopes encased within a polymer.

Polymeric radiation-sources

This invention relates to radioactive, bone-seeking, pharmaceutical compositions that are administered multiple times to a patient, have a lower impurity profile, a longer shelf life, and are less expensive to prepare.

Method of use for therapeutic bone agents

Described are methods and compositions for processes of preparing a radioactive solution of Sn-117m tetraiodide. Aspects include reacting a radioactive solid Sn containing Sn-117m with a solution of Iin an organic solvent at a temperature and for a duration sufficient to result in the formation of Sn-117m tetraiodide. Then, the organic solvent is removed by evaporation to leave dry Sn-117m tetraiodide. The organic solvent is a low boiling point solvent capable of dissolving Iand Sn tetraiodide. The organic solvent is selected from the group consisting of an alcohol and a chlorinated solvent. In embodiments may be selected from the group consisting of dichloromethane, trichloromethane, tetrachloromethane, or mixtures thereof. In embodiments, the organic solvent excludes alcohol. The Imay be in a slight molar excess to the radioactive solid Sn. The method may further include distilling the reactants to remove excess Ifrom the distillate.

Process for producing radioactive dry Sn-117M tetraiodide radiochemical

This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.

Radioactive compositions and methods for their therapeutic use

This invention relates to radioactive, bone-seeking, pharmaceutical methods, compositions and formulations that have a lower impurity profile, a longer shelf life, improved availability and are less expensive to prepare. The compositions of this invention can be conveniently prepared in a timely manner resulting in improved availability and delivery of the drugs to patients.

High purity therapeutic bone agents

A method of purifying a high specific activity Sn-117m composition is provided that includes extracting an iodide complex of Sn-117m with an organic solvent from an acidic aqueous cadmium solution comprising a dissolved irradiated cadmium target, an acid, and a source of iodide. The organic solvent layer comprising the iodide complex of Sn-117m is substantially reduced in cadmium content. The Sn-117m may be back extracted into an aqueous solution.

High purity SN-117M compositions and methods of preparing same

Tin-117m somatostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic. Also, if desired, it can be administered at a dose that is necrotic and/or induces necrosis, but only to cells within 290 microns of the tin-117m atom. A novel somatostatin analogue is also disclosed, as well as novel methods to produce the tin labeled analogues and antagonists.

Tin-117m somatostatin receptor binding compounds and methods

An ophthalmic radiation device using a polymeric radiation-source implemented as either a polymer molecularly bonded with a radioisotope or a polymeric encasement of a radioisotope.

Radioactive epoxy in ophthalmic brachytherapy

Growing community of inventors

Angleton, TX, United States of America

Jaime Simon